• 1
    Hollander D. Intestinal permeability in health and disease. In: Kirsner, JB, ed. Inflammatory Bowel Disease, 3rd edn. Philadelphia: W.B. Saunders, 2000: 4554.
  • 2
    Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108: 156681.
  • 3
    Ukabam SO, Clamp JR, Cooper BT. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 1983; 27: 704.
  • 4
    Andre F, Andre C, Emery Y, Forichon J, Descos L, Minaire Y. Assessment of the lactulose-mannitol test in Crohn's disease. Gut 1988; 29: 5115.
  • 5
    Bjarnason I, O'Morain C, Levi AJ, Peters TJ. Absorption of 51-chromium-label ethylenediaminoacetate in inflammatory bowel disease. Gastroenterology 1983; 85: 31822.
  • 6
    Miki K, Moore DJ, Butler RN, Southcott E, Couper RT, Davidson GP. The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. J Pediatr 1998; 133: 7504.
  • 7
    Sanderson IR, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut 1987; 28: 10736.
  • 8
    Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341: 14379.
  • 9
    D'Inca R, Di Leo V, Corrao G, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999; 94: 295660.
  • 10
    Hilsden RJ, Meddings JB, Hardin J, Gall DG, Sutherland LR. Intestinal permeability and postheparin plasma diamine oxidase activity in the prediction of relapse in Crohn's disease. Inflamm Bowel Dis 1999; 5: 8590.
  • 11
    Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 1522.
  • 12
    Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000; 35: 11639.
  • 13
    Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann Rev Med 2000; 51: 28998.
  • 14
    McKay DM, Baird AW. Cytokine regulation of epithelial permeability and ion transport. Gut 1999; 44: 2839.
  • 15
    Jobin C, Sartor RB. NF-κB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 2000; 6: 20613.
  • 16
    Schmid RM, Adler G. NF-κB/Rel/IκB: Implications in gastrointestinal diseases. Gastroenterology 2000; 118: 120828.
  • 17
    Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 1998; 42: 47784.
  • 18
    Rogler G, Brand K, Vogl D, et al. Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 35769.
  • 19
    Jobin C, Hellerbrand C, Licato LL, Brenner DA, Sartor RB. NF-κB mediates cytokine-induced expression of ICAM-1 in IEC-6 cells, a process blocked by proteasome inhibitors. Gut 1998; 42: 77987.
  • 20
    Neurath M, Pettersson S, Meyer Zum Buschenfelde KH, Strober W. Local administration of antisense phosphothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996; 2: 9981004.
  • 21
    Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Ann Rev Med 2001; 52: 299318.
  • 22
    Thomson ABR, Wild GE. Treatment of patients with Crohn's disease. In: Irvine, EJ, Hunt, RH, eds. Evidence Based Gastroenterology. Lewiston, New York: B.C. Decker, 2001: 24270.
  • 23
    Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94: 55772.
  • 24
    Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression of glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270: 28690.
  • 25
    Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 2836.
  • 26
    Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 24966.
  • 27
    Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterol 1976; 70: 43944.
  • 28
    Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996; 110: 1395403.
  • 29
    Allan A, Jewell DP. In vitro model for the assessment of luminal factors on rectal mucosa. Gut 1983; 24: 8127.
  • 30
    Deryckere F, Gannon F. A one-hour minipreparation technique for the extraction of DNA binding proteins from animal tissues. Biotechniques 1994; 16: 405.
  • 31
    Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Statist Assoc 1958; 53: 45781.
  • 32
    Summers RW, Switz DM, Sessions JT, et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979; 77: 84769.
  • 33
    Modigliani R, Mary JY, Simon JF, et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990; 98: 8118.
  • 34
    Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996; 110: 68893.
  • 35
    Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993; 104: 1293301.
  • 36
    Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomised, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 27882.
  • 37
    Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomised, multicentre trial. Gastroenterology 1999; 116: 5216.
  • 38
    Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a metaanalysis adjusted for confounding variables. Gastroenterology 1997; 113: 146573.
  • 39
    Wright JP, Young GO, Tigler Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 1987; 32: 16470.
  • 40
    Louis E, Belaiche J, Van Kemseke C, et al. A high serum level of interleukin 6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 1997; 9: 93944.
  • 41
    Brignola C, Iannone P, Belloli C, et al. Prediction of relapse in patients with Crohn's disease in remission: a simplified index using laboratory tests, enhanced by clinical characteristics. Eur J Gastorenterol Hepatol 1994; 6: 95561.
  • 42
    Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-α, interleukin-1β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39: 6849.
  • 43
    Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16: 14450.
  • 44
    Dionne S, Ruemmele FM, Laberge S, Seidman EG. The effect of inflammation on the production and release of TNFα by colonic explants in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 143542.
  • 45
    Targan SR, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 102935.
  • 46
    Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease. Lancet 1999; 353: 45961.
  • 47
    Nikolaus S, Raedler A, Kuhbacher T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in failure of Infliximab for Crohn's disease. Lancet 2000; 356: 14759.
  • 48
    Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes. Gastroenterology 1999; 116: 6029.
  • 49
    Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology 2000; 119: 120918.
  • 50
    Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000; 95: 34527.
  • 51
    Thiele K, Bierhaus A, Autschbach F, et al. Cell specific effects of glucocorticoid treatment on the NF-κBp65/IκBα system in patients with Crohn's disease. Gut 1999; 45: 693704.